KBC Group
TRVI icon

KBC Group’s Trevi Therapeutics TRVI Stock Holding History

KBC Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35K Hold
2,464
– – ﹤0.01% 1789
2026
Q2 		$46K Hold
2,464
– – ﹤0.01% 1732
2026
Q1 		$29K Buy
+2,464
New +$27.6K ﹤0.01% 1805

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return
Chapin Davis
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Hilton Head Capital Partners
Hilton Head Capital Partners Hilton Head Island, South Carolina $185M AUM 26.97% 1-Year Est. Return

KBC Group's TRVI Position: Q3 2026 in Review

KBC Group held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 2,464 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

KBC Group first reported a position in TRVI in Q1 2026 and has held it in 3 quarters since. The position peaked at $46K in Q2 2026. 22 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • KBC Group held 2,464 shares of Trevi Therapeutics worth $35K as of Q3 2026.
  • KBC Group left its Trevi Therapeutics share count unchanged in Q3 2026.
  • Trevi Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1789 holding.
  • KBC Group first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Trevi Therapeutics position peaked at $46K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.